trial · primary record
Mezagitamab
Immune Thrombocytopenic Purpura (ITP)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2029-07-29 |
| Primary endpoint | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs |
| Registry ID | NCT06948318 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:45:35.717Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06948318
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.